Safety and efficacy of subcutaneous hepatitis b immunoglobulin after liver transplantation: An open single-arm prospective study

American Journal of Transplantation

Volumn 13, Issue 2, 2013, Pages 348-352

  Di Costanzo, G G ^a   Lanza, A G ^a   Picciotto, F P ^a   Imparato, M ^a   Migliaccio, C ^a   De Luca, M ^a   Scuderi, V ^a   Tortora, R ^a   Cordone, G ^a   Utech, W ^a   Calise, F ^a  

^a CARDARELLI HOSPITAL   (Italy)

Author keywords

hepatitis B immunoglobulin; Hepatitis B virus; liver transplantation; reinfection prophylaxis; subcutaneous administration

Indexed keywords

ADEFOVIR; ENTECAVIR; HEPATITIS B ANTIBODY; LAMIVUDINE; TELBIVUDINE;

ADULT; AGED; ANTIBODY BLOOD LEVEL; ANTIBODY TITER; ANTIVIRAL THERAPY; ARTICLE; CLINICAL EVALUATION; DRUG ABSORPTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG SELF ADMINISTRATION; FEMALE; HEPATITIS B; HUMAN; INJECTION SITE HEMATOMA; INJECTION SITE PRURITUS; INJECTION SITE REACTION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; TREATMENT DURATION;

ADULT; AGED; ANTIVIRAL AGENTS; COHORT STUDIES; FEMALE; HEPATITIS B; HUMANS; IMMUNOGLOBULINS; INJECTIONS, SUBCUTANEOUS; LAMIVUDINE; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; QUALITY OF LIFE; SELF ADMINISTRATION; TREATMENT OUTCOME;

EID: 84873091027     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2012.04319.x     Document Type: Article

References (22)

1. O'Grady JG, Smith HM, Davies SE, et al. Hepatitis B virus re-infection after orthotopic liver transplantation. Serological and clinical implications. J Hepatol 1992; 14: 104-111.
2. Todo S, Demetris AJ, Van Thiel D, Teperman L, Fung JJ, Starzl TE,. Orthotopic liver transplantation for patients with hepatitis B virus related liver disease. Hepatology 1991; 13: 619-626.
3. Samuel D, Muller R, Alexander G, et al. Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med 1993; 329: 1842-1847.
4. McGory RW, Ishitani MB, Oliveira WM, et al. Improved outcome of orthotopic liver transplantation for chronic hepatitis B cirrhosis with aggressive passive immunization. Transplantation 1996; 61: 1358-1364.
5. Sawyer RG, McGory RW, Gaffey MJ, et al. Improved clinical outcomes with liver transplantation for hepatitis B-induced chronic liver failure using passive immunization. Ann Surg 1998; 227: 841-850.
6. Roche B, Feray C, Gigou M, et al. HBV DNA persistence 10 years after liver transplantation despite successful anti-HBS passive immunoprophylaxis. Hepatology 2003; 38: 86-95.
7. Shouval D, Samuel D,. Hepatitis B immune globulin toprevent hepatitis B virus graft reinfection following liver transplantation: a concise review. Hepatology 2000; 32: 1189-1195.
8. Terrault N, Roche B, Samuel D,. Management of the hepatitis B virus in the liver transplantation setting: A European and an American perspective. Liver Transpl 2005; 11: 716-732.
9. Markowitz JS, Martin P, Conrad AJ, et al. Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin. Hepatology 1998; 28: 585-589.
10. Marzano A, Salizzoni M, Debernardi-Venon W, et al. Prevention of hepatitis B virus recurrence after liver transplantation in cirrhotic patients treated with lamivudine and passive immunoprophylaxis. J Hepatol 2001; 34: 903-910.
11. Faust D, Rabenau HF, Allwinn R, Caspary WF, Zeuzem S,. Cost-effective and safe ambulatory long-term immunoprophylaxis with intramuscular instead of intravenous hepatitis B immunoglobulin to prevent reinfection after orthotopic liver transplantation. Clin Transplant 2003; 17: 254-258.
12. Gane EJ, Angus PW, Strasser S, et al. Lamivudine plus low-dose hepatitis B immunoglobulin to prevent recurrent hepatitis B following liver transplantation. Gastroenterology 2007; 132: 931-937.
13. Han SH, Ofman J, Holt C, et al. An efficacy and cost-effectiveness analysis of combination hepatitis B immune globulin and lamivudine to prevent recurrent hepatitis B after orthotopic liver transplantation compared with hepatitis B immune globulin monotherapy. Liver Transpl 2001; 6: 741-748.
14. Jiang L, Yan L, Li B, et al. Prophylaxis against hepatitis B recurrence posttransplantation using lamivudine and individualized low-dose hepatitis B immunoglobulin. Am J Transplant 2010; 10: 1861-1869.
15. Faust D, Rabenau HF, Allwinn R, Caspary WF, Zeuzem S,. Cost-effective and safe ambulatory long-term immunoprophylaxis with intramuscular instead of intravenous hepatitis B immunoglobulin to prevent re-infection after orthotopic liver transplantation. Clin Transplat 2003; 17: 254-258.
16. Franciosi M, Caccamo L, De Simone P, et al. Development and validation of a questionnaire evaluating the impact of hepatitis B immune globulin prophylaxis on the quality of life of liver transplant recipients. Liver Transpl 2012; 18: 332-339.
17. Thürmann PA, Szymanski J, Haffner S, Tenter U, Grieger F, Sonnenburg C,. Pharmacokinetics and safety of a novel anti-HBs-enriched immunoglobulin in healthy volunteers after subcutaneous and intramuscular administration. Eur J Clin Pharmacol 2006; 62: 511-512.
18. Yahyazadeh A, Beckebaum S, Cicinnati V, Klein C, Paul A, Pascher A, Neuhaus R,. Efficacy and safety of subcutaneous human HBV-immunoglobulin (Zutectra ®) in liver transplantation: An open, prospective, single-arm phase III study. Transplant Int 2011; 24: 441-450.
19. Lauchart W, Muller R, Pichlmayr R,. Long-term immunoprophylaxis of hepatitis B virus reinfection in recipients of human liver allografts. Transplant Proc 1987; 19: 4051-4053.
20. Fung J, Cheung C, Chan SC, et al. Entecavir monotherapy is effective in suppressing hepatitis B virus after liver transplantation. Gastroenterology 2011; 141: 1212-1219.
21. Cholongitas E, Vasiliadis T, Antoniadis N, Goulis I, Papanikolaou V, Akriviadis E,. Hepatitis B prophylaxis post liver transplantation with newer nucleos(t)ide analogues after hepatitis B immunoglobulin discontinuation. Transpl Infect Dis. 2012; 14: 479-487.
22. Saab S, Desai S, Tsaoi D, et al. Posttransplantation hepatitis B prophylaxis with combination oral nucleoside and nucleotide analog therapy. Am J Transplant 2011; 11: 511-517.